Live Breaking News & Updates on ஜெஃப்ரி ஹாட்ஃபீல்ட்

Stay updated with breaking news from ஜெஃப்ரி ஹாட்ஃபீல்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biotech Vividion lands $135M in crossover cash, paving a path to the public markets


MedCity News
Biotech Vividion lands $135M in crossover cash, paving a path to the public markets
Vividion Therapeutics has technology that enables it to develop drugs for “undruggable” disease targets. The Series C financing is a crossover round, an indication a biotech is preparing for an IPO.
Shares0
 
Vividion Therapeutics has technology that finds ways to hit promising disease targets that were previously deemed “undruggable.” Now it has $135 million that might allow it to find something else: a public stock listing.
The Series C round of financing announced Wednesday included so-called crossover investors, firms that invest in both public and private companies. Securing crossover investment is one of the steps companies take as they prepare for an IPO. ....

Benjamin Cravatt , Aaron Davis , Jeffrey Hatfield , Scripps Research Institute , Boxer Capital Of Tavistock Group , Bristol Myers Squibb , T Rowe Price Associates , San Diego Based , Scripps Research , Logos Capital , Boxer Capital , Softbank Investment Advisers , Avoro Capital Advisors , Price Associates , Surveyor Capital , Woodline Partners , Acuta Capital , Driehaus Capital , Casdin Capital , Mubadala Capital , Nextech Invest , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , San Francisco ,